Ipinzan

Metformin Hydrochloride and Vildagliptin, the active ingredients in Ipinzan, are a Biguanide and DPP‑4 inhibitor presented as an oral tablet for oral administration. They are used to treat type 2 diabetes mellitus in adult patients by lowering elevated blood glucose levels.

GNH USA supplies Ipinzan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality‑assurance protocols and provides full regulatory documentation to facilitate global procurement and distribution, including batch release certificates and stability data for each shipment.

Ipinzan, containing metformin and vildagliptin, is employed in the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia. - Type 2 diabetes mellitus: improves overall glycemic control when diet and exercise alone are insufficient. - Hyperglycemia: reduces fasting and post‑prandial blood glucose levels. - Adjunct therapy: can be combined with other antidiabetic agents to achieve target HbA1c.

Ipinzan may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate headache episodes. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic complication. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Ipinzan, several precautionary measures should be observed to minimize risk. - Renal function assessment: evaluate eGFR before initiation and periodically thereafter. - Hepatic impairment: use with caution in patients with liver disease. - Risk of lactic acidosis: avoid in patients with severe renal or hepatic dysfunction. - Hypoglycemia monitoring: educate patients on signs, especially if combined with other glucose‑lowering drugs. - Elderly patients: start at lower dose and titrate slowly. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Ipinzan can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast media: may precipitate lactic acidosis; discontinue metformin before use. - Cimetidine: can increase metformin plasma levels, raising risk of adverse effects. - Alcohol: potentiates risk of lactic acidosis when combined with metformin.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: increased risk of hypoglycemia; adjust dose as needed. - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics: can affect renal function, influencing metformin clearance. - NSAIDs: may impair renal function and increase metformin exposure.